EGFR and non-small cell lung carcinoma: We have demonstrated the in vivo antitumor efficacy of P7170 in xenograft models of different erlotinib-sensitive, and –resistant NSCLC cell lines at tolerated doses, and particularly, in xenografts derived from EGFR T790M, L858R erlotinib-resistant cells.